Ocular Therapeutix to Refile Dextenza NDA

Ocular Therapeutix is gearing up to resubmit in the first half of 2018 its New Drug Application for its Dextenza 0.4-mg dexamethasone insert, president and CEO Antony Mattessich reported during the Company Showcase 3 session at OIS@AAO 2017. The firm also expects to reach a couple of other important milestones in the same time frame in 2018, Mattessich said: report topline efficacy results of its intracanalicular travoprost platform; and initiate a Phase I trial of intravitreal OTX-TKI (tyrosine kinase inhibitor). A Phase I trial of intracameral travoprost was started in 3Q 2017, he said.